Asfotase Alfa Treatment Improves Survival for Perinatal and Infantile Hypophosphatasia
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
CONTEXT: Hypophosphatasia (HPP) is an inborn error of metabolism that, in its most severe perinatal and infantile forms, results in 50-100% mortality, typically from respiratory complications. OBJECTIVES: Our objective was to better understand the effect of treatment with asfotase alfa, a first-in-class enzyme replacement therapy, on mortality in neonates and infants with severe HPP. DESIGN/SETTING: Data from patients with the perinatal and infantile forms of HPP in two ongoing, multicenter, multinational, open-label, phase 2 interventional studies of asfotase alfa treatment were compared with data from similar patients from a retrospective natural history study. PATIENTS: Thirty-seven treated patients (median treatment duration, 2.7 years) and 48 historical controls of similar chronological age and HPP characteristics. INTERVENTIONS: Treated patients received asfotase alfa as sc injections either 1 mg/kg six times per week or 2 mg/kg thrice weekly. MAIN OUTCOME MEASURES: Survival, skeletal health quantified radiographically on treatment, and ventilatory status were the main outcome measures for this study. RESULTS: Asfotase alfa was associated with improved survival in treated patients vs historical controls: 95% vs 42% at age 1 year and 84% vs 27% at age 5 years, respectively (P < .0001, Kaplan-Meier log-rank test). Whereas 5% (1/20) of the historical controls who required ventilatory assistance survived, 76% (16/21) of the ventilated and treated patients survived, among whom 75% (12/16) were weaned from ventilatory support. This better respiratory outcome accompanied radiographic improvements in skeletal mineralization and health. CONCLUSIONS: Asfotase alfa mineralizes the HPP skeleton, including the ribs, and improves respiratory function and survival in life-threatening perinatal and infantile HPP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Enzyme-Replacement Therapy in Life-Threatening Hypophosphatasia
Whyte, M. P., Greenberg, C. R., Salman, N. J., Bober, M. B., McAlister, W. H., Wenkert, D., Van Sickle, B. J., Simmons, J. H., Edgar, T. S., Bauer, M. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106173 · Cited by 568
Self-citationEffect of Pyrophosphate on Hydroxyapatite and Its Implications in Calcium Homeostasis
FLEISCH, H., RUSSELL, R. G. G., & STRAUMANN, F. (1966) · Nature · doi:10.1038/212901a0 · Cited by 517
Fraser, D. (1957) · The American Journal of Medicine · doi:10.1016/0002-9343(57)90124-9 · Cited by 389
Normobaric Oxygen Toxicity of the Lung
Deneke, S. M., & Fanburg, B. L. (1980) · New England Journal of Medicine · doi:10.1056/nejm198007103030204 · Cited by 380
Davis, W. B., Rennard, S. I., Bitterman, P. B., & Crystal, R. G. (1983) · New England Journal of Medicine · doi:10.1056/nejm198310133091502 · Cited by 342
Weiss, M. J., Cole, D. E., Ray, K., Whyte, M. P., Lafferty, M. A., Mulivor, R. A., & Harris, H. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.20.7666 · Cited by 340
Self-citationWhyte, M. P., Zhang, F., Wenkert, D., McAlister, W. H., Mack, K. E., Benigno, M. C., Coburn, S. P., Wagy, S., Griffin, D. M., Ericson, K. L., et al. (2015) · Bone · doi:10.1016/j.bone.2015.02.022 · Cited by 264
Self-citationWenkert, D., McAlister, W. H., Coburn, S. P., Zerega, J., Ryan, L. M., Ericson, K. L., Hersh, J. H., Mumm, S. R., & Whyte, M. P. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.454 · Cited by 144
Self-citationGreenberg, C. R., Taylor, C. L. D., Haworth, J. C., Seargeant, L. E., Philipps, S., Triggs‐Raine, B. L., & Chodirker, B. N. (1993) · Genomics · doi:10.1006/geno.1993.1305 · Cited by 135
Genetics of Bone Biology and Skeletal Disease
(2013) · Elsevier eBooks · doi:10.1016/c2010-0-67110-0 · Cited by 111
Cited by
Hypophosphatasia — aetiology, nosology, pathogenesis, diagnosis and treatment
Whyte, M. P. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.14 · Cited by 511
Self-citationAlkaline Phosphatase and Hypophosphatasia
Millán, J. L., & Whyte, M. P. (2016) · Calcified Tissue International · doi:10.1007/s00223-015-0079-1 · Cited by 397
Self-citationAlkaline phosphatase: a novel treatment target for cardiovascular disease in CKD
Haarhaus, M., Brandenburg, V., Kalantar-Zadeh, K., Stenvinkel, P., & Magnusson, P. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.60 · Cited by 316
Pyrophosphate: a key inhibitor of mineralisation
Orriss, I. R., Arnett, T. R., & Russell, R. G. G. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.03.003 · Cited by 181
“The treatment of these diseases remains challenging, but there has been remarkable recent success in treating hypophosphatasia with TNAP enzyme replacement therapy [43].”
BackgroundDental outcomes for children receiving asfotase alfa for hypophosphatasia
Schroth, R. J., Long, C., Lee, V. H. K., Alai-Towfigh, H., & Rockman-Greenberg, C. (2021) · Bone · doi:10.1016/j.bone.2021.116089 · Cited by 29
Monoclonal Antibodies: A Prospective and Retrospective View
Sivaccumar, J., Sandomenico, A., Vitagliano, L., & Ruvo, M. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867327666200219142231 · Cited by 14
Metadata
- Authors
- Whyte, M. P., Rockman-Greenberg, C., Ozono, K., Riese, R., Moseley, S., Melian, A., Thompson, D. D., Bishop, N., & Hofmann, C.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2016-01
- Volume
- 101
- Issue
- 1
- Pages
- 334-342
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2150512825
- Cited by
- 266
- References
- 14
- FWCI
- 20.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.